Advanced Life Sciences Restanza Blocked By New FDA Efficacy Criteria
Executive Summary
Advanced Life Sciences has not given up on developing its investigational drug Restanza (cethromycin) for community acquired pneumonia, despite a June 2 recommendation by the FDA Anti-infective Drugs Advisory Committee that the drug should not be approved for CAP due to lack of efficacy
You may also be interested in...
Non-Inferiority Studies May (Bio)Creep Out Of Limelight After GAO Report
A report on FDA's use of non-inferiority trials by the Government Accountability Office could in fact signal the end of the political wrangling over the study method
Non-Inferiority Studies May (Bio)Creep Out Of Limelight After GAO Report
A report on FDA's use of non-inferiority trials by the Government Accountability Office could in fact signal the end of the political wrangling over the study method
Restanza Superiority Trials Intended To Avoid Non-Inferiority "Quagmire"
Advanced Life Sciences CEO Michael Flavin decided a pair of superiority trials was the best way to prove the efficacy of the company’s Restanza in community-acquired bacterial pneumonia, given the "stalemate" at FDA regarding the use of non-inferiority trials in antibiotics.